References
- Monk BJ, Tewari KS. The spectrum and clinical sequelae of human papillomavirus infection. Gynecol Oncol. 2007;107(2 Suppl 1):S6–S13. doi: 10.1016/j.ygyno.2007.07.076.
- de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology. 2004;324(1):17–27. doi: 10.1016/j.virol.2004.03.033.
- International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Lyon: IARC; 2007.
- Government of Canada. Human papillomavirus vaccine: Canadian Immunization Guide. 2021 https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-9-human-papillomavirus-vaccine.html.
- Villa A, Patton LL, Giuliano AR, et al. Summary of the evidence on the safety, efficacy, and effectiveness of human papillomavirus vaccines: umbrella review of systematic reviews. J Am Dent Assoc. 2020;151(4):245–254.e24. doi: 10.1016/j.adaj.2019.10.010.
- Harper DM, DeMars LR. HPV vaccines - A review of the first decade. Gynecol Oncol. 2017;146(1):196–204. doi: 10.1016/j.ygyno.2017.04.004.
- Bissett SL, Godi A, Jit M, et al. Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: a systematic review and meta-analysis. Vaccine. 2017;35(32):3922–3929. doi: 10.1016/j.vaccine.2017.06.028.
- El-Zein M, Coutlée F, Tellier PP, et al. Human papillomavirus infection and transmission among couples through heterosexual activity (HITCH) cohort study: protocol describing design, dethods, and research goals. JMIR Res Protoc. 2019;8(1):e11284. doi: 10.2196/11284.
- Morais S, Wissing MD, Khosrow-Khavar F, et al. Serologic response to human papillomavirus genotypes among unvaccinated females: findings from the HITCH cohort study. J Infect Dis. 2022;227(10):1173–1184.
- Waterboer T, Sehr P, Michael KM, et al. Multiplex human papillomavirus serology based on in situ-purified glutathione S-transferase fusion proteins. Clin Chem. 2005;51(10):1845–1853. doi: 10.1373/clinchem.2005.052381.
- Mesher D, Thomas SL, Linley E, et al. Post-vaccination HPV seroprevalence among female sexual health clinic attenders in England. Vaccine. 2021;39(30):4210–4218. doi: 10.1016/j.vaccine.2021.05.018.
- Clifford GM, Shin HR, Oh JK, et al. Serologic response to oncogenic human papillomavirus types in male and female university students in busan, South Korea. Cancer Epidemiol Biomarkers Prev. 2007;16(9):1874–1879. doi: 10.1158/1055-9965.EPI-07-0349.
- Prendiville W, Davies P, editors. The health professional’s HPV handbook: human papillomavirus and cervical cancer. London and New York: Taylor & Francis; 2006.
- Mboumba Bouassa RS, Péré H, Jenabian MA, et al. Natural and vaccine-induced B cell-derived systemic and mucosal humoral immunity to human papillomavirus. Expert Rev anti Infect Ther. 2020;18(6):579–607. doi: 10.1080/14787210.2020.1750950.
- Bogaards JA, van der Weele P, Woestenberg PJ, et al. Bivalent human papillomavirus (HPV) vaccine effectiveness correlates with phylogenetic distance from HPV vaccine types 16 and 18. J Infect Dis. 2019;220(7):1141–1146. doi: 10.1093/infdis/jiz280.